Crescita Therapeutics (TSX:CTX) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Debt-to-Equity?

Crescita Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.44 Mil. Crescita Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.82 Mil. Crescita Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$18.82 Mil. Crescita Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Crescita Therapeutics's Debt-to-Equity or its related term are showing as below:

TSX:CTX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.11 Max: 0.34
Current: 0.07

During the past 10 years, the highest Debt-to-Equity Ratio of Crescita Therapeutics was 0.34. The lowest was 0.06. And the median was 0.11.

TSX:CTX's Debt-to-Equity is ranked better than
77.37% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSX:CTX: 0.07

Crescita Therapeutics Debt-to-Equity Historical Data

The historical data trend for Crescita Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Debt-to-Equity Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.06

0.14

0.08

0.07

Crescita Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.07	0.07	0.07	0.07

Competitive Comparison of Crescita Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Debt-to-Equity falls into.

Crescita Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Crescita Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.439	+	0.815)	/	18.822
	=	0.07

Crescita Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.439	+	0.815)	/	18.822
	=	0.07

Crescita Therapeutics (TSX:CTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Crescita Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (TSX:CTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CRRTF:USA

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Crescita Therapeutics (TSX:CTX) Headlines

No Headlines